Loading
CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
Acts as an inhibitor of protein phosphatase PP2A. Promotes anchorage-independent cell growth and tumour formation by preventing dephosphorylation of MYC, thereby stabilising MYC in human malignancies. Together with TOPBP1, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Gemcitabine.
In plain words · CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.
Acts as an inhibitor of protein phosphatase PP2A. Promotes anchorage-independent cell growth and tumour formation by preventing dephosphorylation of MYC, thereby stabilising MYC in human malignancies.
No product in this corpus aims at CIP2A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA CIP2A: RNA low tissue specificity; high antibody staining in 18 normal tissues; highest cancer staining head and neck cancer (4 of 4 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Pancreatic ductal adenocarcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CIP2A tissue; Open Targets ENSG00000163507 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 2000, "Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:29302 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8TCG1 (protein name, function text, keywords and locations (REST API)); CIViC gene CIP2A (2 evidence items, 0 assertions, 2 variants; diseases: Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0))
Acts as an inhibitor of protein phosphatase PP2A. Promotes anchorage-independent cell growth and tumour formation by preventing dephosphorylation of MYC, thereby stabilising MYC in human malignancies. Together with TOPBP1, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei. Micronuclei, which are frequently found in cancer cells, consist of chromatin surrounded by their own nuclear membrane: following breakdown of the micronuclear envelope, a process associated with chromothripsis, the CIP2A-TOPBP1 complex tethers chromosome fragments during mitosis to ensure clustered segregation of the fragments to a single daughter cell nucleus, facilitating re-ligation with limited chromosome scattering and loss. Location: Cytoplasm; Chromosome (UniProt). Locus 3q13.13 (HGNC).
RNA: low tissue specificity, detected in some normal tissues.
Medium: Adrenal gland, Appendix, Bone marrow, Caudate, Cervix, Endometrium, Epididymis, Esophagus.
Medium only: lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CIP2A" OR ABSTRACT:"CIP2A" OR TITLE:"cellular inhibitor of PP2A" OR ABSTRACT:"cellular inhibitor of PP2A" OR TITLE:"KIAA1524" OR ABSTRACT:"KIAA1524") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CIP2A, not a curated reading list.